Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine

• Status: Terminated
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether administrating of Amantadine (a dopamine agonist) to patients suffering from Parkinson disease during the perioperative period is safe, and to asses potential benefits of this treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rabin Medical Center
• Treatments: Amantadine

Criteria

Inclusion Criteria:

• Patient with a diagnosis of Parkinson Disease refered for surgery at our institution.

Exclusion Criteria:

• Cardiac and neurosurgical procedures

• Inability to sign informed Consent

• allergy to Amantadine

• Congestive heart failure

• Arrythmia (including bradycardia below 55 bpm)

• renal failure (creatinin above 1.5)

• If a patient will develop agitation or delirium lasting longer then 8 hours he will not receive the second dose of amantadine.